Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% ...

Moderna's full pipeline may fuel long-term growth.

Piper Sandler expects Moderna to generate $2.07 billion in product sales in 2026, driven largely by its next‑generation COVID vaccine, mNEXSPIKE, according to Investing.com. The FDA is set to review ...

Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as well as business outlook for 2026 and beyond. It also outlined some expected ...

Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it’s been on the rise. This other biotech has proven itself as a long-term winner. Though Moderna stock ...

The FDA had previously rejected Moderna's application, refusing even to review it after concluding Moderna hadn't done sufficient safety testing. Now, Moderna is promising to do additional testing to ...